Palvella Therapeutics, Inc.
125.10USD
-1.2900 (-1.02%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on PVLA.
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | 25.9M | 42.8M | — | — | 0.0 | 24.6M |
| Q1 | 11.0M | 1.9M | 53.0K | — | — | — |
| Q2 | 3.7M | 20.1M | 0.0 | — | — | — |
| Q3 | 5.4M | 19.5M | 0.0 | — | 0.0 | — |
| Q4 | 5.8M* | 1.3M* | — | — | 0.0 | — |
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | -.090 | .434 | -1.57 | -3.71 | -6.43 | -7.98 |
| Q1 | -.574 | -2.83 | -.308 | -.740 | -1.20 | — |
| Q2 | -1.15 | .724 | -.494 | -.860 | -1.52 | — |
| Q3 | -.026 | -1.74 | -.788 | -1.03 | -1.74 | — |
| Q4 | -.022* |
Fiscal period: Reported, Estimated. Reported figures: SEC filings (EDGAR). Estimates are sell-side consensus for periods that have not reported. Cells marked * were synthesized from the annual filing less the year-to-date figures, because the quarter was not filed on its own. Earnings per share are restated onto today's share basis, so a period before a stock split is comparable with the ones after it.
Revenue to net income
| 4.31* |
| -.355* |
| -1.13* |
| -2.06 |
| — |
Debt level and coverage